Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 4/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13836753 | 0.86 | KDM4E (0.41) | KDM4EYTHDC1STAT3HIF1APDE3B | |
| SCHEMBL30356824 | 0.84 | PRKAG1 (0.46) | KDM4EYTHDC1STAT3HIF1ADYRK1A | |
| SCHEMBL492537 | 0.84 | PRKAG1 (0.46) | KDM4EYTHDC1STAT3HIF1ADYRK1A | |
| SCHEMBL29958456 | 0.83 | DYRK1A (0.42) | KDM4EYTHDC1STAT3HIF1ADYRK1A | |
| SCHEMBL12480678 | 0.83 | DYRK1A (0.42) | KDM4EYTHDC1STAT3HIF1ADYRK1A | |
| SCHEMBL16516966 | 0.82 | KDM4E (0.65) | KDM4EYTHDC1STAT3HIF1ADYRK1A | |
| Hydrochloric Acid SCHEMBL30645338 | 0.81 | DYRK1A (0.41) | KDM4EYTHDC1STAT3HIF1ADYRK1A | |
| SCHEMBL18587756 | 0.79 | KDM4E (0.68) | KDM4ESTAT3HIF1A | |
| SCHEMBL492254 | 0.79 | DYRK1A (0.41) | KDM4EYTHDC1STAT3HIF1ADYRK1A | |
| SCHEMBL12468205 | 0.78 | DYRK1A (0.43) | DYRK1AWNT1AHRGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867226-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-14 | — | — | EP | disclosed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2867226-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002051-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | KDM4E 3988/4885YTHDC1 3744/4885STAT3 3121/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | KDM4E 4092/4885YTHDC1 3815/4885STAT3 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.